Abbott Laboratories Company Earnings: Where's the Wow?

Abbott Labs  (NYSE: ABT  )  reported solid third-quarter results but didn't wow anyone. Shares were down as much as 4% in intraday trading Wednesday after the company's earnings announcement.

Earnings grew 10.2% compared to the same quarter in 2011. This level beat Abbott's prior guidance and analyst estimates. However, reported revenue fell by 0.4% compared to last year.

In an analysis prior to the earnings release, I examined three keys to Abbott's continued success. Let's look at how the company fared during the third quarter against these three criteria.

1. Humira horsepower
The big key for Abbott right now is its multi-purpose drug Humira. Reported sales for third quarter grew 10.1% year-on-year. Not coincidentally, that figure nearly matches the company's overall sales growth for the quarter.

Third-quarter sales for Humira were basically flat compared to the second quarter, but the source of the revenue changed noticeably. In the second quarter, international sales accounted for 55% of total revenue. However, international sales fell to 51% of the total during the third quarter.

Humira battles against Enbrel, marketed by Amgen (Nasdaq: AMGN  ) and Pfizer (NYSE: PFE  ) , in the rheumatoid and psoratic arthritis markets.  It competes against Johnson & Johnson's (NYSE: JNJ  ) Remicade for treatment of these conditions plus others, including  Crohn's disease and ulcerative colitis. All are blockbuster drugs, but Humira stands to be the biggest winner of them all.

2. Generic gyrations
Abbott saw a decline of 1% in the first quarter and 6% in the second quarter for its "established pharmaceuticals" segment, which sells generic drugs. The company blamed European "pricing pressures for these drops.

This decline continued in the third quarter. Reported established pharmaceuticals sales fell by 7.3% compared to the same quarter in 2011. Humira's strength compensates for this continued slide for now. However, that won't last much longer. Abbott's spin-off of a new company, AbbVie, in 2013 means that the generics business can't count on help from Humira going forward.

3. Currency comeback
In the analysis prior to the company's third-quarter results, I predicted that the falling dollar during much of the third quarter could help the company improve earnings. This prediction turned out to be wrong.

Currency fluctuations served as a drag on Abbott's earnings in the second quarter. The company stated then that unfavorable foreign exchange caused sales to be 4.7% less than they would have been otherwise. 

Unfortunately, things weren't much better in the third quarter. The company cited a 4.5% unfavorable foreign exchange impact on sales. Perhaps continued weakness of the dollar could help Abbott in the days ahead, but I won't make any more predictions on this front.

Going forward
Abbott's earnings results for this quarter weren't overly exciting, but they weren't horrible, either. The company also narrowed full-year guidance from the $5.00-$5.10 range to $5.06-$5.08. That reflects a fairly positive outlook going forward.

I like the company for its dividends -- 355 quarters in a row paying dividends makes for a nice track record. I also like the upcoming spin-off of AbbVie. Humira continues to show considerable strength. There are few promising drugs in the pipeline as well.

Perhaps neither Abbott nor AbbVie will be"wow" stocks, but they could be good additions to investors' portfolios over the long run. 

If you're looking for some other long-term investing ideas, let me invite you to read the Fool's brand-new special report: "The 3 Dow Stocks Dividend Investors Need." It's absolutely free, so just click here and get your copy today.

Foll contributor Keith Speights has no positions in the stocks mentioned above. The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services recommend Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (1) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On October 18, 2012, at 5:54 PM, SteveTheInvestor wrote:

    I'm still not sure what to make of the upcoming spin-off. I've held ABT for several years and had recently placed a trailing stop on it because of this uncertainty. The trade executed a bit above $70 and netted me a capital gain equal to about 12 years of dividends. I hated to lose the dividend stream, but I can't complain by any means.

    For now, I'm going to sit on the sidelines and see how the spin-off unfolds and who does what with dividends.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2062092, ~/Articles/ArticleHandler.aspx, 10/1/2014 10:37:41 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Apple's next smart device (warning, it may shock you

Apple recently recruited a secret-development "dream team" to guarantee its newest smart device was kept hidden from the public for as long as possible. But the secret is out. In fact, ABI Research predicts 485 million of this type of device will be sold per year. But one small company makes Apple's gadget possible. And its stock price has nearly unlimited room to run for early-in-the-know investors. To be one of them, and see Apple's newest smart gizmo, just click here!


Advertisement